RxDoctor Payments Data

Sarita Sharma, MD

Psychiatry · Augusta, GANPI 1225013568

Payments from drug & device makers

$2,918in general payments, 2019–2025

Across 132 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$359
  • Indivior Inc.$282
  • Johnson & Johnson$250
  • Lundbeck LLC$214
  • Teva Pharmaceuticals USA, Inc.$172
  • plus $382 from 11 others

What the payments were for

  • Food & beverage$2,909100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,918 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$3,322
Medicare patients
20
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate44$131,918
IngrezzaValbenazine Tosylate11$96,373
UzedyRisperidone26$86,743
AustedoDeutetrabenazine11$79,422
AristadaAripiprazole Lauroxil21$58,592
LybalviOlanzapine/Samidorphan Malate22$35,613
Haloperidol Decanoate112$8,496
Varenicline Tartrate11$3,267
Fluphenazine Decanoate13$1,916
Divalproex Sodium25$1,267
Risperidone58$1,212
Clozapine24$1,149
Benztropine Mesylate57$966
Quetiapine Fumarate22$903
Lorazepam40$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Uzedy, Austedo$172$166,16537 claims
Johnson & JohnsonInvega Sustenna$250$131,91844 claims
Alkermes, Inc.Aristada, Lybalvi$1,259$94,20543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →